Literature DB >> 24933331

A REVELation in non-small-cell lung cancer treatment?

Tony S K Mok1, Herbert H Loong2.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 24933331     DOI: 10.1016/S0140-6736(14)60895-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  1 in total

1.  A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.

Authors:  Edward B Garon; Jeffrey D Neidhart; Nashat Y Gabrail; Moacyr R de Oliveira; Jai Balkissoon; Fairooz Kabbinavar
Journal:  Onco Targets Ther       Date:  2016-11-30       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.